Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05784597 | A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors(FAPrimo) | completed | Phase 1 | 18 | Philogen S.p.A.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03238196 | Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer | completed | Phase 1 | 35 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT02229084 | Vaccination of High Risk Breast Cancer Patients | completed | Phase 1 / Phase 2 | 58 | University of ArkansasOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02938442 | Vaccination of Triple Negative Breast Cancer Patients | completed | Phase 1 / Phase 2 | 16 | University of ArkansasOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT01921335 | ARRY-380 + Trastuzuamab for Breast w/ Brain Mets | completed | Phase 1 | 41 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT00719173 | Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer(NRR) | completed | Phase 1 | 19 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT02980341 | Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 182 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Oct 30, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT03207529 | Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer | completed | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors(PACT) | completed | Phase 1 | 164 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 27, 2024 | clinicaltrials |
| NCT02389842 | PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib(PIPA) | completed | Phase 1 | 79 | Royal Marsden NHS Foundation TrustOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT03251378 | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers | completed | Phase 1 | 129 | Hutchison Medipharma LimitedINDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT02780401 | Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission(WOKVAC) | completed | Phase 1 | 32 | University of WashingtonOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04187898 | Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer | completed | Phase 1 | 59 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT03343054 | A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 28 | PfizerINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT01606241 | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03560531 | A Study of ZN-c5 in Subjects With Breast Cancer | completed | Phase 1 / Phase 2 | 181 | Zeno Alpha Inc.INDUSTRY | 9 | Aug 9, 2024 | clinicaltrials |
| NCT03451162 | Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer | completed | Phase 1 | 14 | Genentech, Inc.INDUSTRY | 2 | Aug 5, 2024 | clinicaltrials |
| NCT02061423 | HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy(Neoadjuvant) | completed | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03154281 | Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | completed | Phase 1 | 14 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT04728035 | Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance | completed | Phase 1 | 119 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT05578820 | Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid | completed | Phase 1 | 21 | Gene Surgery LLCINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05364255 | A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833 | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT00194714 | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab | completed | Phase 1 / Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT02599714 | Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer(PASTOR) | completed | Phase 1 | 54 | AstraZenecaINDUSTRY | 2 | Jun 6, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT01618357 | Pre-Operative Radiation and Veliparib for Breast Cancer | completed | Phase 1 | 19 | Richard ZellarsOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03256344 | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | completed | Phase 1 | 36 | AmgenINDUSTRY | 6 | May 14, 2024 | clinicaltrials |
| NCT03149081 | A "Window Trial" on Boswellia for Breast Cancer Primary Tumors | completed | Phase 1 | 46 | Medical University of South CarolinaOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT03330561 | PRS-343 in HER2-Positive Solid Tumors | completed | Phase 1 | 85 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03650348 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | completed | Phase 1 | 41 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04535323 | Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT02996825 | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | completed | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01761240 | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Mar 29, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04134884 | Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer | completed | Phase 1 | 34 | Kathy MillerOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03619681 | Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer | completed | Phase 1 | 63 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT00424164 | Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer(LAPATAM) | completed | Phase 1 | 20 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04834778 | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | completed | Phase 1 | 23 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 19, 2024source: clinicaltrials